|
Market Cap (2-Nov) $454,393,888 (0th) |
Close (30-Jun) $0.220 |
Volume (30-Jun) 0 |
Shortsold (27-Oct) 12,677,800 (7.75%) (38th) |
|
52w High $6.49 |
52w Low $2.00 |
P/E - |
EPS -0.17 |
Conference Call - Update on US FDA Application
AYA released this announcement to the ASX on 17 June 2022, 8:18. The announcement is not marked as price sensitive, and is 1 page(s) in length and 93.01kb in size.
You can view all announcements from AYA and see how they appear on a price chart on the announcements page.
At the date of this announcement, AYA was 0.009% short sold according to ASIC data. It was ranked the 577th most shorted stock on the ASX. It is now ranked as the 38th most shorted stock on the ASX with 7.748% of total shares short sold as of the latest reported data (27 October 2026).
| Other Recent Announcements from AYA | |
|---|---|
| Notification of cessation of securities - AYA | 19 June 2023, 18:00 |
| Application for quotation of securities - AYA | 14 June 2023, 18:25 |
| Secondary Trading Notice | 14 June 2023, 18:25 |
| Conference Call - Update on US FDA Application | 17 June 2022, 8:18 |
| Update on US FDA Application for Artrya Salix | 16 June 2022, 15:55 |
| Change of Director's Interest Notice - John Barrington | 18 May 2022, 8:18 |
| Artrya Signs First U.S. Hospital Clinical Partnership | 9 May 2022, 8:39 |
If you were already registered, log in here.